![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.contractpharma.com/contents/view_breaking-news/2022-08-03/fda-approves-first-biosimilar-to-lucentis/?widget=listSection
https://www.lexblog.com/2022/05/19/teva-receives-approval-for-first-ophthalmology-biosimilar-in-europe/
https://www.businesswire.com/news/home/20211004005408/en/Polpharma-Biologics-Group-Announces-that-the-Biologics-License-Application-BLA-Submitted-by-its-Joint-Venture-Bioeq-for-its-Biosimilar-Ranibizumab-has-Been-Accepted-for-Review-by-the-U.S.-Food-and-Drug-Administration-FDA
https://www.formycon.com/en/press-release/formycon-and-bioeq-announce-submission-of-the-biologics-license-application-bla-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-u-s-food-and-drug-administration-fda/
https://www.formycon.com/en/press-release/formycon-and-bioeq-announce-submission-of-the-marketing-authorization-application-for-fyb201-a-biosimilar-candidate-to-lucentisr1-ranibizumab-to-the-european-medicines-agency-ema/
https://www.prnewswire.com/news-releases/bioeq-announces-coherus-as-marketing-and-distribution-partner-for-its-biosimilar-to-lucentis-ranibizumab-in-the-us-300953223.html